SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): October 30, 2003
Ciphergen Biosystems, Inc.
(Exact name of Registrant as specified in its charter)
Delaware 000-31617 33-059-5156
(State or other jurisdiction of [Commission (I.R.S. Employer
incorporation or organization) File Number] Identification Number)
6611 Dumbarton Circle
Fremont, CA 94555
(Address of principal executive offices)
(510) 505-2100
(Registrant's telephone number, including area code)
The information in this Current Report on Form 8-K, including the
exhibits, is furnished pursuant to Item 12 - Results of Operations and Financial
Condition and shall not be deemed "filed" for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities under that Section. Furthermore, the information in this Current
Report on Form 8-K, including the exhibits, shall not be deemed to be
incorporated by reference into the filings of Ciphergen Biosystems, Inc. under
the Securities Act of 1933, as amended.
Item 9. Regulation FD Disclosure (pursuant to "Item 12. Results of Operations
and Financial Condition").
A copy of the press release issued October 30, 2003 by the Registrant
announcing Third Quarter 2003 earnings is furnished under Item 12 of this
Current Report on Form 8-K as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Ciphergen Biosystems, Inc.
(Registrant)
Date: October 30, 2003 By: /s/ William E. Rich
-----------------------------------
William E. Rich
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number Description
------- ----------------------------------------------------------------------
99.1 Press Release issued by Ciphergen Biosystems, Inc. on October 30, 2003